PHAR Stock Analysis: Buy, Sell, or Hold?
PHAR - Pharming Group N.V. ADS, each representing 10 ordinary shares
$20.47
-0.22 (-1.06%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 12, 2026
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PHAR shows positive signals but monitor for confirmation. Market pricing in 5.3% growth. Moderate conviction.
💡 BUY OPPORTUNITY: PHAR shows positive signals but monitor for confirmation. Market pricing in 5.3% growth. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $20.47, which is considered extended relative to its 30-day fair value range of $17.15 to $19.84. From a valuation perspective, the stock is trading at a premium (Forward PE: 322.4) compared to its historical average (276.2). At these levels, the market is pricing in 5.3% annual earnings growth.
Technical Outlook: Technically, PHAR is in a strong uptrend. Immediate support is located at $17.25, while resistance sits at $21.34.
Market Sentiment: PHAR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.00 (+51.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PHAR is in a strong uptrend. Immediate support is located at $17.25, while resistance sits at $21.34.
Market Sentiment: PHAR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.00 (+51.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$17.15 -
$19.84
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 51.4% below Wall St target ($31.00)
- BULLISH: Expecting earnings turnaround to 5.3% growth with 30.0% revenue growth
Fair Price Analysis
30-Day Fair Range
$17.15 -
$19.84
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$17.25
Resistance Level
$21.34
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
322.36
Wall Street Target
$31.00
(+51.4%)
Revenue Growth (YoY)
30.0%
Earnings Growth (YoY)
-61.5%
Profit Margin
0.1%
Valuation Premium vs History
+5.3% premium
PE vs Historical
322.4 vs 276.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.3%
(market-implied from PE analysis)
1-Year Target
$21.55
(+5%)
2-Year Target
$22.70
(+11%)
3-Year Target
$23.90
(+17%)
3-Yr Target (if PE normalizes)
(PE: 322→276)
PE COMPRESSION
$20.48
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 322.4, Growth: 202.4%)
$69.09
(+238%)
Base:
(SPY PE: 22.3, Growth: 202.4%)
$4.78
(-77%)
Bear:
(PE: 19.0, Growth: 202.4%)
$4.06
(-80%)
Last updated: February 01, 2026 4:50 AM ET
Data refreshes hourly during market hours. Next update: 5:50 AM
Data refreshes hourly during market hours. Next update: 5:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 59 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$141 | 59 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$42 | 64 BUY |
Advanced PHAR Option Strategies
Professional options setups generated by AI based on today's PHAR price and gamma walls.
